TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00196339
Drug: Cyproterone acetate 15
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 15 mg
Study: NCT00196339
Drug: Cyproterone acetate 25
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 25 mg
Study: NCT01714843
Drug: linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT02210247
Drug: EXPAREL
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03875092
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT03875092
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion Carboplatin dose should not exceed 900 mg.
Study: NCT03875092
Drug: Saline placebo for pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT02573025
Drug: PEG-IFN alfa-2a BA-free formulation (Test)
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
Study: NCT03205761
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
Study: NCT01088880
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02375880
Drug: DKN-01
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous (IV) infusion.
Study: NCT02375880
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV infusion.
Study: NCT02375880
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT04420585
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
Study: NCT02573025
Drug: PEG-IFN alfa-2a market formulation (Reference)
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
Study: NCT02307201
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient will receive magnesium sulfate for 24 hours postpartum
Study: NCT02066818
Drug: Lidocaine/tetracaine patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02066818
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02715700
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
Study: NCT04540926
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 pneumonia patients treated with oral CsA at a dose of 1-2 mg /kg / day divided into two doses, for 7 days, since entering to hospitalization.
Study: NCT01868555
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study: NCT01201811
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
Study: NCT02715700
Drug: Doravirine
Normalized name: Doravirine
DrugBank: Doravirine (DB12301)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Doravirine 100 mg oral tablet once per day.
Study: NCT00977756
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg daily, dosing by weight in Group I
Study: NCT02263248
Drug: venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
Study: NCT01868555
Drug: insulin degludec/insulin aspart 30
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study: NCT01868555
Drug: insulin degludec/insulin aspart 45
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
Study: NCT02169609
Drug: Dinutuximab. Immunotherapy
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy.
Study: NCT00549666
Drug: Lurasidone 40 mg
Normalized name: lurasidone 40 mg oral tablet
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 40 mg days 12-21 once daily
Study: NCT00549666
Drug: Ortho Tri-Cyclen
Normalized name: Ortho Tri-Cyclen
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ortho Tri-Cyclen during 28-day lead in period
Study: NCT02263248
Drug: buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
Study: NCT00009763
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00009763
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00907933
Drug: SB-705498
Normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg intranasal SB-705498
Study: NCT00907933
Drug: SB-705498
Normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5mg intranasal SB-705498
Study: NCT00907933
Drug: SB-705498
Normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg intranasal SB-705498
Study: NCT00907933
Drug: SB-705498
Normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg intranasal SB-705498
Study: NCT00907933
Drug: SB-705498
Normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12mg intranasal SB-705498
Study: NCT00907933
Drug: SB-705498
Normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg intranasal SB-705498 for 14 days bid
Study: NCT00907933
Drug: SB-705498
Normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12mg intranasal SB-705498 14 days bid
Study: NCT02228304
Drug: NT-503-3 ECT implantation
Normalized name: ECT-001 expanded UCB
DrugBank: CT-001 (DB18284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
Study: NCT00672386
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
Study: NCT00977756
Drug: Tenofovir (TDF)
Normalized name: emtricitabine/tenofovir (TDF) 200 mg-300 mg ORAL TABLET
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg daily
Study: NCT00977756
Drug: Etravirine (ETV)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg BID
Study: NCT00977756
Drug: Darunavir (DRV)
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosing by weight
Study: NCT00977756
Drug: Maraviroc (MVC)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg BID in groups J and K; 600 mg BID in group L
Study: NCT02857426
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02551523
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 92 patients will be simplified to once daily dolutegravir monotherapy
Study: NCT02123615
Drug: Gadolinium For abdomen
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study: NCT02123615
Drug: Gadolinium For abdomen
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study: NCT02123615
Drug: Gadolinium For abdomen
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
Study: NCT00487058
Drug: Gimatecan
Normalized name: Gimatecan
DrugBank: Gimatecan (DB06721)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03319784
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
Study: NCT03587142
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buspirone tablet
Study: NCT03306901
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3,200 \~ 4,000mg/m2 intravenously for 4 to 5 days.
Study: NCT02123615
Drug: Gadolinium For lower back
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subdermally with ASIS Device for 30 patients.
Study: NCT02123615
Drug: Gadolinium For lower back
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for \<40kg) or 29cc normal saline (for \>40kg) subcutaneously for 30 patients.
Study: NCT03306901
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45\~60mg intravenously over 1 hour on day 1
Study: NCT02707458
Drug: Probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US.
Study: NCT02768662
Drug: OTO-104
Normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection of 12 mg OTO-104
Study: NCT02123615
Drug: Gadolinium For lower back
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Study: NCT00259922
Drug: Alvimopan
Normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg QD
Study: NCT00259922
Drug: Alviompan
Normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg BID
Study: NCT00677443
Drug: S-1 & Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
Study: NCT04111159
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
Study: NCT00296790
Drug: zolpidem tartrate
Normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 24
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
Study: NCT03656198
Drug: Sterile Water Injection
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subcutaneously at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 36
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
Study: NCT02123615
Drug: Efficacy of Gammagard subdermally at Week 12
Normalized name: Gammagard
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.